GBT

Global Blood
NASDAQ

Real-time Quotes | Nasdaq Last Sale

53.57
-0.53
-0.98%
Closed 16:00 09/22 EDT
OPEN
54.16
PREV CLOSE
54.10
HIGH
54.16
LOW
52.02
VOLUME
867.49K
TURNOVER
--
52 WEEK HIGH
87.54
52 WEEK LOW
39.95
MARKET CAP
3.29B
P/E (TTM)
-11.3265
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Wells Fargo: These 2 Stocks Could Deliver Triple-Digit Wins
Was the recent market volatility just a fake out? After notching an all-time high on September 2, fears related to overheated valuations spurred a rapid correction, marking the first material correction of the current bull market. However, this doesn’t mean the bears have been vindicated, so says Wells
TipRanks · 4d ago
Announcing: Global Blood Therapeutics (NASDAQ:GBT) Stock Increased An Energizing 102% In The Last Three Years
Global Blood Therapeutics, Inc. (NASDAQ:GBT) shareholders might be concerned after seeing the share price drop 19% in...
Simply Wall St. · 5d ago
Hedge Funds Have Never Been This Bullish On Global Blood Therapeutics Inc (GBT)
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend
Insider Monkey · 09/15 05:43
Wall Street’s top analysts are recommending stocks like Uber and Lovesac amid market volatility
CNBC used TipRanks analyst ranking service to pinpoint Wall Street's best-performing stocks, like Uber and Lovesac.
CNBC.com · 09/13 10:52
Global Blood Therapeutics (GBT) Investor Presentation - Slideshow
The following slide deck was published by Global Blood Therapeutics, Inc. in conjunction with this event.
Seekingalpha · 09/11 21:39
GBT and Sickle Cell Disease Association of America to Host 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference
Keynote Address by U.S. Assistant Secretary for Health Admiral Brett P. Giroir, M.D. Discussion to Focus on SCD Treatment Progress and Management During COVID-19 Pandemic SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT)
GlobeNewswire · 09/09 13:00
Global Blood Therapeutics inks distribution pact with Biopharma-MEA for SCD med
Global Blood Therapeutics (GBT) +1.5% AH, has entered into an exclusive agreement with Biopharma-Middle East and Africa (Biopharma-MEA) for the distribution of Oxbryta (voxelotor) tablets in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.Oxbryta is a once-daily, oral therapy
Seekingalpha · 09/08 20:51
GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta® (voxelotor) in Six Middle Eastern Countries
More than 100,000 people age 12 years and older with sickle cell disease (SCD) in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab EmiratesSOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it has entered
GlobeNewswire · 09/08 20:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GBT stock price target is 110.44 with a high estimate of 152.00 and a low estimate of 64.00.
EPS
Institutional Holdings
Institutions: 361
Institutional Holdings: 68.24M
% Owned: 111.22%
Shares Outstanding: 61.36M
TypeInstitutionsShares
Increased
77
5.19M
New
85
869.71K
Decreased
80
6.13M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.48%
Pharmaceuticals & Medical Research
+0.12%
Key Executives
President/Chief Executive Officer/Director
Ted Love
Chief Financial Officer
Jeffrey Farrow
Chief Human Resource Officer
Eric Fink
Chief Scientific Officer
Brian Cathers
Other
Jung Choi
Other
David Johnson
Other
Tricia Suvari
Lead Director/Independent Director
Mark Perry
Director
Deval Patrick
Independent Director
Willie Brown
Independent Director
Scott Morrison
Independent Director
Glenn Pierce
Independent Director
Philip Pizzo
Independent Director
Dawn Svoronos
Independent Director
Wendy Yarno
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average GBT stock price target is 110.44 with a high estimate of 152.00 and a low estimate of 64.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GBT
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Global Blood Therapeutics Inc stock information, including NASDAQ:GBT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GBT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GBT stock methods without spending real money on the virtual paper trading platform.